Osbourn takes CEO role at Alchemab Therapeutics
Alchemab is a pharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals.
Osbourn has led all aspects of Alchemab's platform development and drug discovery activities to date and brings to the CEO role more than 30 years of biopharmaceutical industry experience.
Prior to co-founding Alchemab in 2019, she served as Vice President of R & D at MedImmune, the biologics arm of AstraZeneca, where she contributed to the development of antibody phage display technology and the discovery and development of several marketed antibody therapies including HUMIRA® (adalimumab) and IMFINZI® (durvalumab).
She is a Venture Partner at SV Health Investors, has served as a Director of Babraham Bioscience Technologies, Cambridge Enterprise, the Crick Translational Advisory Group, and was Chair of the UK BioIndustry Association.
Osbourn says: “I have had the great pleasure of helping to lead the company since the beginning. We have a fantastic team who have been integral to Alchemab's growth from a concept through to a robust and novel antibody identifying engine.
“With several novel targets and therapeutic antibodies in preclinical development, I am delighted to lead Alchemab as CEO through this next phase towards achieving our ultimate goal of discovering and developing ground-breaking treatments for patients.”
Young Kwon added: “The time is right to hand over the reins to Jane to lead the company as CEO. Jane has been my partner in growing Alchemab and has played a central role in establishing the company's robust, well-tuned antibody discovery platform.
“I am very pleased to hand over to Jane whose scientific and organisational expertise will ensure the successful progress of Alchemab as it enters its next phase of growth.”
Alchemab studies the unique antibody response of resilient individuals to develop drugs based on naturally derived antibodies to prevalent, hard-to-treat diseases which do not have disease modifying therapies.
Its platform integrates data mining of patient-derived immune responses with the latest multi-disciplinary drug discovery approaches to understand what keeps people well. The goal is to unlock nature's engineering and harness the incredible human immune system to find breakthrough drugs.
Through collaborations with world class institutions, Alchemab taps into large ecosystems and millions of patient samples which it analyses using advanced computational approaches.
Alchemab was founded in 2019 with seed funding from SV Health Investors and has already raised more than $80 million from a blue chip syndicate of specialist backers. The company is headquartered in London with labs in Cambridge UK and Boston US.